Journal
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
Volume 17, Issue 6, Pages 319-329Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-022-00685-1
Keywords
Myeloproliferative Neoplasms; MPN; Myeloid diseases; Janus kinase; JAK2; Clonal hematopoiesis
Categories
Funding
- National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) [R01HL131835]
- Gabrielle's Angel Foundation
- Leukemia & Lymphoma Society
- Starr Cancer Consortium [I15-0026]
- German Cancer Aid (Mildred-Scheel scholarship) [70114570]
Ask authors/readers for more resources
This review summarizes the etiology, molecular genetics, and treatment advances in myeloproliferative neoplasms (MPNs). Recent progress in understanding the pathogenesis of MPNs has been made, but there are still challenges in clonally selective therapy. The future goal is to translate advances in biological understanding into improved patient treatment.
Purpose of Review Myeloproliferative neoplasms (MPNs) are chronic hematological malignancies characterized by increased proliferation of MPN stem and myeloid progenitor cells with or without bone marrow fibrosis that typically lead to increased peripheral blood cell counts. The genetic and cytogenetic alterations that initiate and drive the development of MPNs have largely been defined, and we summarize these here. Recent Findings In recent years, advances in understanding the pathogenesis of MPNs have defined a long-preclinical phase in JAK2-mutant MPN, identified genetic loci associated with MPN predisposition and uncovered mechanistic insights in CALR-mutant MPN. The integration of molecular genetics into prognostic risk models is well-established in myelofibrosis and ongoing studies are interrogating the prognostic implications of concomitant mutations in ET and PV. Despite all these advances, the field is deficient in clonally selective therapies to effectively target the MPN clone at any stage of disease, from pre-clinical to advanced. Although the biological understanding of the pathogenesis of MPNs has progressed quickly, substantial knowledge gaps remain, including in the molecular mechanisms underlying MPN progression and myelofibrotic transformation. An ongoing goal for the MPN field is to translate advances in biological understanding to improved treatments for patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available